Apnea, Stroke and Incident Cardiovascular Events (ASCENT)

May 20, 2022 updated by: University Hospital, Grenoble

Sleep Apnea Syndrome and Incidence of Major Adverse Cardiac and Cerebrovascular Events (MACCEs) After a First Stroke

This prospective cohort study aims to compare the proportion of cardiac or cerebrovascular events after a first stroke, a first transient ischemic attack (TIA) or recurrent TIA, between sleep-disordered breathing (SDB) and non-SDB (control) patients, one year after SDB diagnosis, performed 3 months after stroke onset.

The primary outcome is a composite endpoint composed of cardiac or cerebrovascular events regrouping: death from any cardiac or cerebrovascular cause, non-fatal stroke, and non-fatal acute coronary disease.

1620 patients, in the acute phase of a first stroke, TIA or recurrent TIA will be included in the cohort.

Clinical, neuroimaging, sensorimotor, cognitive and biological parameters will be collected at inclusion. Three months after stroke or TIA onset, polysomnography will be performed for SDB diagnosis. Patients will be considered as having SDB for an Apnea-Hypopnea Index (AHI) > 15 events/hour, or to the control group otherwise. The same clinical, imaging, cognitive and biological assessments than during the first visit will be performed; incident (new) cardiovascular events will be collected. Three months later, and at 1, 2, 3, 4 and 5 years after SDB diagnosis, the same clinical, cognitive, sensorimotor, and sleep-related evaluations will be performed. In addition to the aforementioned parameters, incident cardiovascular outcomes will be collected, at the same time points. The primary study outcome will be retrieved one year after stroke onset.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This is a prospective cohort study that aims at comparing the proportion of incident cardiovascular events after a first stroke, first transient ischemic attack (TIA) or recurrent TIA, between sleep-disordered breathing patients (SDB, defined as an apnea-hypopnea index > 15 events/hour) and non-SDB patients, one year after SDB diagnosis performed by polysomnography 3 months after the cerebrovascular event.

The primary outcome is a composite endpoint composed of cardiac or cerebrovascular events (Major Adverse Cardiovascular Events, MACCEs), regrouping: death from any cardiac or cerebrovascular cause, non-fatal stroke, non-fatal acute coronary event. Secondary outcomes include secondary cardiac and cerebrovascular events; stroke-related functional criteria; lesion-related criteria obtained from morphological MRI; scores on questionnaires assessing the quality of life, depression and sleep; functional, cognitive and sensorimotor evaluations; locomotion tests; and sleep-related criteria.

1620 patients, aged 18 to 85 years, in the acute phase (<72h) of a first stroke, first or recurrent TIA, and with a score on the modified Rankin Scale (mRS) ≤1 before stroke onset, will be included in the cohort. All patients included in the study will be followed for 5 years. The schedule of follow-up will be as follow :

  • Selection visit (Days 0 to 3): verification of eligibility criteria, patients' or relatives' information, informed consent signature.
  • Inclusion visit (Days 4 to 7): clinical history and treatments, clinical evaluation and anthropometrical parameters, stroke-related criteria (including score on the National Institute of Health Stroke Scale), functional, cognitive, and sensorimotor evaluation, walking and locomotion tests, questionnaires, stroke imagery by magnetic resonance imagery, blood sampling.
  • SDB diagnosis (Month 3): the same clinical, MRI and biological parameters will be collected and the same questionnaires will be fulfilled by the patients. In addition, they will undergo polysomnography to assess their SDB status. Patients will be assigned to the SDB group if the AHI > 15 events/hour; otherwise they will be assigned to the control group. Patients assigned to the SDB group will be proposed a treatment for their SDB according to standard care procedures.
  • Clinical follow-up: sleep and neurological; (initial 3 months and then annually after SDB diagnosis up to 5 years after SDB diagnosis): retrieval of new cardiac or cerebrovascular events (primary study outcome (MACCEs)), stroke-related parameters, questionnaires, functional, cognitive, and sensorimotor evaluations, locomotion tests, sleep follow-up (adherence to SDB treatment, tolerance, efficacy). Biological sampling will also be done at 1, 2 and 5 years after SDB diagnosis.

Ancillary study - CAtSS (Carotid, Atherosclerosis, Stroke and Sleep apnea) Conjointly to the previously described ASCENT protocol, an ancillary study will be proposed to the subgroup of patients eligible for carotid surgery (endarterectomy) following their cerebrovascular event.

The purpose of this ancillary study is to evaluate the impact of SDB and SDB treatment on the evolution of the carotid plaque after surgery. For the patients who accepted to participate to this ancillary study, the degree of carotid stenosis and the artery wall thickness (intima-media thickness, assessed by echo-Doppler) will be measured during the inclusion visit, at 3 months, 6 months, and at each annual visit. During surgery, a fragment of carotid plaque will be kept for morphologic and histologic analyses as well as miRNAs dosing, miARNs being recognized as indicators of carotid plaque instability. Plasmatic and urine samples will also be collected for miRNA analyses.

Study Type

Observational

Enrollment (Anticipated)

1620

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • France
      • Grenoble, France, 38043
        • Recruiting
        • University Hospital Grenoble
        • Sub-Investigator:
          • Marie DESTORS, MD
        • Contact:
        • Contact:
        • Sub-Investigator:
          • Chrystel Saint Raymond, MD
        • Sub-Investigator:
          • Olivier Detante, Pr
        • Sub-Investigator:
          • Isabelle FAVRE-WIKI, MD
        • Sub-Investigator:
          • Katia GARAMBOIS, MD
        • Sub-Investigator:
          • Raphaëlle Spear, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients in the acute phase (<72h) of a first stroke or initial/recurrent TIA, admitted in the stroke unit of the Grenoble Alpes University Hospital.

Description

Inclusion Criteria:

  • Male or female, aged 18 to 85 years

  • Admitted in the stroke unit no later than 72h after the onset of stroke symptoms:

    • First stroke confirmed by computed tomography scan or magnetic resonance imaging, whatever the localization
    • Initial or recurrent TIA, as defined by a brief and sudden neurological dysfunction for which an ischemic cause is presumed, with symptoms lasting less than 24 hours, and/or with no visible lesion on neuroimaging evaluation.
  • Score on the Modified Ranking scale (mRS) ≤1 before stroke
  • Signed informed consent by patient or his/her relative if not able
  • Patient eligible to carotid endarterectomy (for ancillary study only)

Exclusion Criteria:

  • Pregnant or breastfeeding women
  • Past history of stroke
  • Inability to follow rehabilitation procedure
  • Patients with ongoing treatment for SDB
  • Exclusion period for another study
  • Patients not affiliated to a French social and health insurance system or equivalent
  • Prisoners or patients who require protection by the law

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Sleep-disordered breathing group
Sleep-disordered breathing (SDB) patients (AHI>15/h, measured by polysomnography performed 3 months after stroke)
Device: Treatment according to standard care recommandation
SDB treatment according to standard care recommandation: Continuous Positive Airway Pressure (CPAP), Mandibular Advancement Device, Positionnal Therapy, Adaptive Servo-Ventilation (ASV), Non-Invasive Ventilation (NIV)
Control group
Control patients with no SDB (AHI<15/h, measured by polysomnography performed 3 months after stroke)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence of Major Adverse Cardiac or Cerebrovascular Events (MACCEs)
Time Frame: 1 year after SDB diagnosis
Composite endpoint composed of cardiac or cerebrovascular events regrouping: death from cardiac of cerebrovascular cause, non fatal stroke (either ischemic or hemorrhagic), and non-fatal acute coronary disease
1 year after SDB diagnosis

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence of Major Adverse Cardiac or Cerebrovascular Events (MACCEs)
Time Frame: 5 years after SDB diagnosis
Composite endpoint composed of cardiac or cerebrovascular events regrouping: death from cardiac of cerebrovascular cause, non fatal stroke (either ischemic or hemorrhagic), and non-fatal acute coronary disease
5 years after SDB diagnosis
Prevalence of secondary cardiac or cerebrovascular events
Time Frame: 5 years after SDB diagnosis
Composite endpoint composed of cardiac or cerebrovascular events regrouping: transient ischemic attack (TIA), any acute coronary disease, hospitalization for any cardio-vascular cause and peripheral artery disease
5 years after SDB diagnosis
Change in BMI from inclusion to 5 years
Time Frame: at inclusion, and at each visit up to 5 years after SDB diagnosis
Change in body mass index (BMI), defined as weight (Kg)/height (m)². This will be calculated at inclusion and at each visit
at inclusion, and at each visit up to 5 years after SDB diagnosis
Change in waist, neck, and abdominal circumferences, from inclusion visit to 5 years
Time Frame: at inclusion, and at each visit up to 5 years after SDB diagnosis
Change in waist, neck and abdominal circumferences in cm. This will be measured at inclusion and at each visit.
at inclusion, and at each visit up to 5 years after SDB diagnosis
Change in NIHSS score from inclusion to 5 years
Time Frame: at inclusion, and at each visit up to 5 years after SDB diagnosis
Stroke severity assessed by National Institute of Health Stroke Scale (NIHSS). This tool is composed of 15 items, each assessing specific abilities. (0: no stroke symptoms; 1 to 4: minor stroke; 5 to 15: moderate stroke; 16-20: moderate to severe stroke; >20 : severe stroke). The scale will be administered at each visit.
at inclusion, and at each visit up to 5 years after SDB diagnosis
ABCD² score at inclusion
Time Frame: at inclusion
Score evaluating the risk for stroke after a transient ischemic attack (TIA). The scale ranges from 0 (low level) to 7 (high level). 0 to 3: low risk; 4 to 5: moderate, 6 to 7: high risk
at inclusion
Clinical outcome: change in modified Ranking Sale (mRS) from inclusion to 5 years
Time Frame: at inclusion, and at each visit up to 5 years after SDB diagnosis
Scale assessing functional outcome after stroke, ranging from 0 (no symptoms at all) to 5 (severe disability), measured at each visit
at inclusion, and at each visit up to 5 years after SDB diagnosis
Clinical outcome: change in Functional Independence Measure (FIM) from inclusion to 5 years
Time Frame: at inclusion, and at each visit up to 5 years after SDB diagnosis
Scale assessing functional outcome after stroke, ranging from 18 (totally dependent) to 126 (totally independent), measured at each visit
at inclusion, and at each visit up to 5 years after SDB diagnosis
Clinical outcome: change in Stroke Impact Scale (SIS-16) from inclusion to 5 years
Time Frame: at inclusion, and at each visit up to 5 years after SDB diagnosis
This scale assess patient's health after stroke, through 16 items evaluating functional independence and mobility. This scale ranges from 16 (total independance) to 80 (total dependancy). The scale will be administer at each visit
at inclusion, and at each visit up to 5 years after SDB diagnosis
Clinical outcome: change Patient Health Questionnaire (PHQ-9) from inclusion to 5 years
Time Frame: at inclusion, and at each visit up to 5 years after SDB diagnosis
Scale assessing patient's depression symptoms, administered at each visit. The scale ranges from 0 (no depression) to 27 (severe depression).
at inclusion, and at each visit up to 5 years after SDB diagnosis
Clinical outcome: change Fugl-Meyer Assessment Scale from inclusion to 5 years
Time Frame: at inclusion, and at each visit up to 5 years after SDB diagnosis
Scale assessing sensori-motor upper extremity function in post-stroke patients, administered at each visit. The maximal possible score is 226, which corresponds to a complete sensori-motor recovery.
at inclusion, and at each visit up to 5 years after SDB diagnosis
Change in walking and locomotion abilities: nFAC score, from inclusion to 5 years
Time Frame: at inclusion, and at each visit up to 5 years after SDB diagnosis
Evaluation of ambulation abilities, from 0 (cannot walk) to 8 (able to walk independantly)
at inclusion, and at each visit up to 5 years after SDB diagnosis
Change in walking and locomotion abilities: 10m walking test, from inclusion to 5 years
Time Frame: at inclusion, and at each visit up to 5 years after SDB diagnosis
Evaluation of speed on the 10m walking test
at inclusion, and at each visit up to 5 years after SDB diagnosis
Change in daytime sleepiness: score on the Epworth Sleepiness Scale, from inclusion to 5 years
Time Frame: at inclusion, and at each visit up to 5 years after SDB diagnosis
Daytime sleepiness score measured by Epworth Sleepiness Scale. The scale ranges from 0 (no sleepiness) to 24 (severe sleepiness)
at inclusion, and at each visit up to 5 years after SDB diagnosis
Change in daytime sleepiness: score Berlin Questionnaire for Sleep Apnea (BQSA)
Time Frame: at inclusion, and at each visit up to 5 years after SDB diagnosis
Sleep apnea screening questionnaire that identifies the risk (from low to high) of sleep disordered breathing
at inclusion, and at each visit up to 5 years after SDB diagnosis
Assessment of sleep and fatigue: score change on Chalder Fatigue Scale from inclusion to 5 years
Time Frame: at inclusion, and at each visit up to 5 years after SDB diagnosis
Questionnaire evaluating the severity of tiredness, on a scale ranging from 0 (no fatigue) to 33 (severe), administered at each visit
at inclusion, and at each visit up to 5 years after SDB diagnosis
Assessment of sleep and fatigue: score change on Fatigue Severity Scale (FSS) from inclusion to 5 years
Time Frame: at inclusion, and at each visit up to 5 years after SDB diagnosis
Questionnaire evaluating the severity of tiredness, on a scale ranging from 9 (no fatigue) to 63 (severe), administered at each visit
at inclusion, and at each visit up to 5 years after SDB diagnosis
Assessment of sleep and fatigue: score change on Pichot's Fatigue Scale from inclusion to 5 years
Time Frame: at inclusion, and at each visit up to 5 years after SDB diagnosis
Questionnaire evaluating the severity of tiredness, on a scale ranging from 0 (no fatigue) to 32 (severe), administered at each visit
at inclusion, and at each visit up to 5 years after SDB diagnosis
Change in depression symptoms from inclusion to 5 years : Pichot's Depression Scale (QD2A)
Time Frame: at inclusion, and at each visit up to 5 years after SDB diagnosis
Questionnaire evaluating depression symptoms through right/false responses to 13 items, administered at each visit (score: 0 to 13)
at inclusion, and at each visit up to 5 years after SDB diagnosis
Change in cognitive abilities from inclusion to 5 years: scores on the Montreal Cognitive Assessment Test
Time Frame: at inclusion, and at each visit up to 5 years after SDB diagnosis
Global assessment of cognitive functions, evaluating on 30 points and in 10 minutes short-term memory, verbal fluency, visuoconstructive abilities, executive functions, attention, working memory, language and spatiotemporal orientation. The test will be administered at each visit.
at inclusion, and at each visit up to 5 years after SDB diagnosis
Change in cognitive abilities from inclusion to 5 years : scores on the Frontal Assessment Battery
Time Frame: at inclusion, and at each visit up to 5 years after SDB diagnosis
Short screening test evaluating executive function, on a scale from 0 (severe disability) to 18 (no disability)
at inclusion, and at each visit up to 5 years after SDB diagnosis
Change in cognitive abilities from inclusion to 5 years : Language Screening Test (LAST)
Time Frame: at inclusion, and at each visit up to 5 years after SDB diagnosis
Rapid evaluation of language abilities (oral expression and comprehension) through 15 items (total score: 15).
at inclusion, and at each visit up to 5 years after SDB diagnosis
Prevalence of SDB assessed by polysomnography
Time Frame: 3 months post-stroke
Prevalence of SDB, assessed by polysomnography, and defined as AHI (Apnea-Hypopnea Index >15/h)
3 months post-stroke
Prevalence of respiratory disorders
Time Frame: 3 months post-stroke
Respiratory assessments : spirometry, plethysmography, CO diffusion, blood gas measurement, measurement of ventilatory response to CO2
3 months post-stroke
Change in adherence to SDB treatments, from 6 months to 5 years after SDB diagnosis
Time Frame: from 6 months and at each visit up to 5 years after SDB diagnosis
Treatment adherence, assessed by CPAP monitoring (mean hours/night) if applicable
from 6 months and at each visit up to 5 years after SDB diagnosis
Stroke characteristics : lesion volume
Time Frame: At inclusion
Stroke volume in mm3, determined on MRI/CT scan
At inclusion
Concentration of C-Reactive protein
Time Frame: 3 months
Concentration of C-Reactive protein by blood sampling
3 months
Change in degree of carotid stenosis (ancillary study)
Time Frame: from 3 months to 5 years after SDB diagnosis
NASCET (North American Symptomatic Carotid Endarterectomy) evaluation of carotid stenosis in percent by Echo-doppler
from 3 months to 5 years after SDB diagnosis
Change in intima-media thickness (ancillary study) from 3 months to 5 years
Time Frame: from 3 months to 5 years after SDB diagnosis
Measurement of carotid intima-media thickness (in mm) by Echo-Doppler
from 3 months to 5 years after SDB diagnosis
Plasmatic and urinary miRNAs (ancillary study)
Time Frame: from 3 months to 5 years after SDB diagnosis
miRNA expression and modulation in plasma and urine
from 3 months to 5 years after SDB diagnosis
miRNAs in carotid artery plaque (ancillary study)
Time Frame: At baseline (carotid surgery)
miARNs expression and modulation in carotid artery plaque
At baseline (carotid surgery)
Prevalence of post-operative complication (ancillary study)
Time Frame: from 3 months to 5 years after SDB diagnosis
Prevalence of post-operative complication defined as post-operative hematomy, nerve palsy of nerves X and XII, per - post-operative ischemic or hemorragic strokes, myocardial infarction, death
from 3 months to 5 years after SDB diagnosis
Adipose tissue analysis (ancillary study)
Time Frame: At baseline (carotid surgery)
Morphological analysis of adipose tissue collected during endarteriectomy, expression of membrane and lipidic and glycemic markers, expression of inflammatory markers
At baseline (carotid surgery)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Grenoble

Investigators

  • Principal Investigator: Renaud Tamisier, MD, PhD, MBA, University Hospital, Grenoble

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 13, 2020

Primary Completion (Anticipated)

June 1, 2030

Study Completion (Anticipated)

June 1, 2035

Study Registration Dates

First Submitted

March 25, 2020

First Submitted That Met QC Criteria

May 18, 2020

First Posted (Actual)

May 22, 2020

Study Record Updates

Last Update Posted (Actual)

May 23, 2022

Last Update Submitted That Met QC Criteria

May 20, 2022

Last Verified

May 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2019-A03085-52 (Registry Identifier: CPP Sud-Méditerranée II)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stroke

Clinical Trials on Treatment according to standard care recommandation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe